{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Procedure', 'Notes', 'If', 'If', 'Follow', 'Visit', '1', '2', '2.5', '3', '3.5', '4', '4.25', '4.5', '5', '6', '7', 'needed', 'needed', 'up', 'Every visit window +/- 3 days', '20 or', 'If', 'If', '(except for visit 3 which is +/- 2', 'Week', '-4 to -2', '0', '1', '2', '3', '4', '5', '6', '8', '12', '16', 'as', 'needed', 'needed', 'days); The Screening period', 'needed', 'includes up to a 4 weeks Run-in', 'period', 'X', 'X', 'Hematology with differential', 'X', 'X', 'X', 'See Appendix 2 (Section 10.2).', 'See Appendix 2 (Section 10.2).', 'Coagulation test (INR only)', '*Includes INR at Visit 2', 'If Hepatitis C test is positive or', 'Hepatitis B surface antigen and', 'X', 'indeterminant, a confirmatory', 'Hepatitis C antibody', 'test will be reflexively performed', 'to confirm the results.', 'See Appendix 2 (Section 10.2),', 'Table 4 and Appendix 6', '(Section 10.6). Includes total bile', 'Clinical chemistry', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'acids at every visit.', 'If ALP > 1xULN, include', 'fractionation of ALP', 'Urinalysis', 'X', 'X', 'X', 'See Appendix 2 (Section 10.2).', 'Nasal mucosal lining fluid sample', 'X', 'X', 'X', 'See Section 8.6.1.', 'Subject to record time of last', 'morning dose taken at home prior', 'to Week 4, 12, and 16 visits. For', 'Week 4, 12, and 16 visits, subject', 'X', 'X', 'X', 'X', 'to bring the dose to clinic to be', 'Pharmacokinetic (PK) sample', 'taken after the PK blood draw.', 'See Section 8.5. At Week 4 visit,', 'an additional PK sample will be', 'taken at approximately 2.5 hours', 'post-dose.', 'Biomarker sample (blood, urine)', 'X', 'X', 'X', 'X', 'See Sections 8.6.2 and 8.6.3.', 'RNA transcriptome research', 'X', 'X', 'X', 'X', 'See Section 8.6.3.', '16', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Procedure', 'Notes', 'If', 'If', 'Follow', 'Visit', '1', '2', '2.5', '3', '3.5', '4', '4.25', '4.5', '5', '6', '7', 'needed', 'needed', 'up', 'Every visit window +/- 3 days', '20 or', 'If', 'If', '(except for visit 3 which is +/- 2', 'Week', '-4 to -2', '0', '1', '2', '3', '4', '5', '6', '8', '12', '16', 'as', 'needed', 'needed', 'days); The Screening period', 'needed', 'includes up to a 4 weeks Run-in', 'period', '* If consent provided, sample', 'X', 'can be collected at any visit', 'Pharmacogenetic sample', '*', '*', '*', 'post-randomization or any bio-', 'sample used for this purpose; see', 'Section 8.7.', 'Other Administrative Procedures', 'If subject discontinues IP, but', 'Dispense investigational product (IP)', 'stays on study, do not dispense IP', 'at subsequent visits (Section 7.1).', 'Collect used IP/conduct accountability', 'X', 'Dispense MFNS for use as background', 'X', 'therapy', 'Instruct subjects on Diary use, if all', 'Eligible subjects enter the Run-in', 'screening eligibility criteria are met', 'period and complete morning and', 'evening Diary until Week 20.', 'Review Diary', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Complete eCRF', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Abbreviations: CRS = chronic rhinosinusitis; CT = computed tomography; eCRF = electronic case report form; EW = early withdrawal;', 'IP =investigational product; MFNS = mometasone furoate nasal spray; RNA = ribonucleic acid.', '17', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}